AU2013366450A1 - Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins - Google Patents

Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins Download PDF

Info

Publication number
AU2013366450A1
AU2013366450A1 AU2013366450A AU2013366450A AU2013366450A1 AU 2013366450 A1 AU2013366450 A1 AU 2013366450A1 AU 2013366450 A AU2013366450 A AU 2013366450A AU 2013366450 A AU2013366450 A AU 2013366450A AU 2013366450 A1 AU2013366450 A1 AU 2013366450A1
Authority
AU
Australia
Prior art keywords
seq
protein
cdtb
cdta
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013366450A
Other languages
English (en)
Inventor
Cindy Castado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2013366450A1 publication Critical patent/AU2013366450A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013366450A 2012-12-23 2013-12-20 Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins Abandoned AU2013366450A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1223342.5 2012-12-23
GBGB1223342.5A GB201223342D0 (en) 2012-12-23 2012-12-23 Immunogenic composition
PCT/EP2013/077762 WO2014096393A1 (en) 2012-12-23 2013-12-20 Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins

Publications (1)

Publication Number Publication Date
AU2013366450A1 true AU2013366450A1 (en) 2015-07-23

Family

ID=47682553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013366450A Abandoned AU2013366450A1 (en) 2012-12-23 2013-12-20 Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins

Country Status (12)

Country Link
US (2) US9669083B2 (enExample)
EP (1) EP2934579B1 (enExample)
JP (1) JP6515036B2 (enExample)
CN (1) CN105120892B (enExample)
AR (1) AR094275A1 (enExample)
AU (1) AU2013366450A1 (enExample)
BR (1) BR112015014727B8 (enExample)
CA (1) CA2894951C (enExample)
ES (1) ES2748054T3 (enExample)
GB (1) GB201223342D0 (enExample)
SG (1) SG11201504701UA (enExample)
WO (1) WO2014096393A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
CN103974718A (zh) * 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ES2749701T3 (es) * 2014-06-25 2020-03-23 Glaxosmithkline Biologicals Sa Composición inmunógena de Clostridium difficile
IL269258B2 (en) * 2017-03-15 2023-09-01 Novavax Inc Methods and compositions for inducing immune responses against Clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
EP4003256B1 (en) 2019-07-30 2025-12-10 The Government of The United States, as Represented by The Secretary of The Army Layered composite for scar treatment and prevention
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) * 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JP6121421B2 (ja) * 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes

Also Published As

Publication number Publication date
US20150313985A1 (en) 2015-11-05
JP6515036B2 (ja) 2019-05-15
US9669083B2 (en) 2017-06-06
CA2894951C (en) 2023-05-09
CA2894951A1 (en) 2014-06-26
US20180043005A1 (en) 2018-02-15
EP2934579A1 (en) 2015-10-28
BR112015014727A2 (pt) 2017-10-10
ES2748054T3 (es) 2020-03-12
WO2014096393A1 (en) 2014-06-26
BR112015014727B1 (pt) 2022-08-02
BR112015014727B8 (pt) 2022-09-20
GB201223342D0 (en) 2013-02-06
EP2934579B1 (en) 2019-08-07
CN105120892A (zh) 2015-12-02
JP2016504993A (ja) 2016-02-18
CN105120892B (zh) 2020-07-31
SG11201504701UA (en) 2015-07-30
AR094275A1 (es) 2015-07-22

Similar Documents

Publication Publication Date Title
EP2934579B1 (en) Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins
JP5922074B2 (ja) 結核菌(Mycobacteriumtuberculosis)ポリペプチドおよびその融合物を含む免疫原性組成物
EP2637687B1 (en) Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2007079684A1 (fr) Proteines de fusion de mycobacterium tuberculosis et utilisations
JP2016502551A (ja) 免疫原性組成物
RS55707B1 (sr) Izolovani polipeptid toksin a i toksin b proteina c. difficile i njihova upotreba
EP2978447B1 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
BR112019004913B1 (pt) Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
WO2010064243A1 (en) GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
JP2020100625A (ja) クロストリジウム・ディフィシル免疫原性組成物
JP2015528457A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
EP2838990A1 (en) Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
EP2981287A2 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CA2952118C (en) Clostridium difficile immunogenic composition
JP2015532594A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
WO2009053723A1 (en) Small protective epitopes of the yersinia pestis v antigen and dna vaccines encoding these

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted